

Vanessa Roldan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4763098/vanessa-roldan-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

187
papers

6,593
citations

37
h-index

76
g-index

219
ext. papers

7,887
ext. citations

4.3
avg, IF

5.48
L-index

#	Paper	IF	Citations
187	Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial.. <i>Journal of Thrombosis and Thrombolysis</i> , 2022 , 1	5.1	
186	Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 787235	5.4	1
185	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021 , 23, 1612-1676	3.9	99
184	Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs Real-world? <i>International Journal of Clinical Practice</i> , 2021 , 75, e13888	2.9	1
183	Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
182	Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	2
181	Relationship between multimorbidity and outcomes in atrial fibrillation. <i>Experimental Gerontology</i> , 2021 , 153, 111482	4.5	4
180	Anticoagulant therapy in patients with congenital FXI deficiency. <i>Blood Advances</i> , 2021 , 5, 4083-4086	7.8	
179	Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHADS-VASc in real-world and clinical trial patients.. <i>European Journal of Internal Medicine</i> , 2021 ,	3.9	1
178	Factor XII in PMM2-CDG patients: role of N-glycosylation in the secretion and function of the first element of the contact pathway. <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 280	4.2	3
177	Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 2360-2369	6.4	3
176	ALG12-CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant. <i>Molecular Genetics & Genomic Medicine</i> , 2020 , 8, e1304	2.3	10
175	Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1200-1207	7	23
174	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 749-757	0.7	11
173	Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIA study. <i>European Journal of Internal Medicine</i> , 2020 , 78, 63-68	3.9	1
172	Influence of the matrix type over the concentration of GDF-15. <i>Journal of Investigative Medicine</i> , 2020 , 68, 1402-1404	2.9	
171	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1867-1881	4.1	2

170	Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
169	Factor XI, much more than an innocent observer. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3172-3173	3.4	1
168	A nurse-led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. <i>International Journal of Clinical Practice</i> , 2020 , 74, e13634	2.9	5
167	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1901-1919	7	36
166	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. <i>Stroke</i> , 2019 , 50, 1372-1379	6.7	29
165	Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1409-1418	7	4
164	Riesgo embólico, riesgo isquémico y riesgo hemorrágico. <i>Revista Espanola De Cardiologia Suplementos</i> , 2019 , 18, 3-8	0.2	
163	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. <i>BMJ Open</i> , 2019 , 9, e033712	3	0
162	Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under vitamin K antagonists. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019 , 112, 183-188	2.7	3
161	Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1477-1491	6.1	12
160	Increasing therapy-related myeloid neoplasms in multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13050	4.6	8
159	Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency. <i>Thrombosis Research</i> , 2018 , 163, 64-70	8.2	9
158	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e12929	4.6	1
157	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. <i>International Journal of Clinical Practice</i> , 2018 , 72, e13069	2.9	1
156	MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 892-902	9.4	34
155	Quality of oral anticoagulation with vitamin K antagonists in Real-world Patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. <i>Europace</i> , 2018 , 20, 1435-1441	3.9	33
154	Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 279-287	7	8
153	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. <i>Clinical Therapeutics</i> , 2018 , 40, 114-122	3.5	17

152	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1065-1073	6.4	18
151	Manejo perioperatorio y periprocedimiento del tratamiento antitrombótico: documento de consenso de SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT y AEU. <i>Revista Española De Cardiología</i> , 2018 , 71, 553-564	1.5	61
150	Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. <i>Journal of General Internal Medicine</i> , 2018 , 33, 847-854	4	12
149	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018 , 20, 1231-1242	3.9	148
148	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018 , 39, 1330-1393	9.5	1094
147	Enhancing the Real world prediction of cardiovascular events and major bleeding with the CHADS-VASc and HAS-BLED scores using multiple biomarkers. <i>Annals of Medicine</i> , 2018 , 50, 26-34	1.5	14
146	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2018 , 82, 1286-1292	2.9	3
145	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018 , 122, 785-792	3	8
144	Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU. <i>Revista Española De Cardiología (English Ed)</i> , 2018 , 71, 553-564	0.7	12
143	miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis. <i>PLoS ONE</i> , 2018 , 13, e0198932	3.7	12
142	Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality. <i>Cardiology Journal</i> , 2018 , 25, 151-154	1.4	4
141	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in Real-world Atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. <i>International Journal of Cardiology</i> , 2018 , 254, 125-131	3.2	15
140	Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHADS-VASc and HAS-BLED. <i>American Heart Journal</i> , 2018 , 197, 27-34	4.9	7
139	Comentarios a la guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular. <i>Revista Española De Cardiología</i> , 2017 , 70, 2-8	1.5	8
138	Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. <i>Scientific Reports</i> , 2017 , 7, 41565	4.9	25
137	Regulation of TFPI expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens. <i>Scientific Reports</i> , 2017 , 7, 43500	4.9	16
136	Evaluation of HAS-BLED and ORBIT Bleeding Risk Scores in Nonvalvular Atrial Fibrillation Patients Receiving Oral Anticoagulants. <i>Revista Española De Cardiología (English Ed)</i> , 2017 , 70, 132-133	0.7	
135	Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017 , 120, 2176-2181	3	14

134	Long-term bleeding risk prediction in Real world Patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1848-1858	7	44
133	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. <i>Scientific Reports</i> , 2017 , 7, 12066	4.9	14
132	Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHADS-VASc Scores. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	26
131	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 1051-1062	4.1	13
130	Applicability of the modified CHADS-VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. <i>European Journal of Internal Medicine</i> , 2017 , 38, e21-e22	3.9	2
129	Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients. <i>Biological Research for Nursing</i> , 2017 , 19, 198-205	2.6	1
128	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1448-1454	7	55
127	Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2261-2266	7	40
126	Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion. <i>Circulation Journal</i> , 2016 , 80, 605-12	2.9	3
125	Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. <i>Circulation Journal</i> , 2016 , 80, 2102-8	2.9	12
124	Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016 , 69, 134-40	0.7	3
123	Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery. <i>Europace</i> , 2016 , 18, 1328-34	3.9	4
122	The SAME-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 177-87	2.5	15
121	Repercusiones en la posología de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la función renal de los pacientes con fibrilación auricular e insuficiencia cardiaca aguda reciente. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 134-140	1.5	8
120	Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 117-25	7	9
119	MiRNA-Based Regulation of Hemostatic Factors through Hepatic Nuclear Factor-4 Alpha. <i>PLoS ONE</i> , 2016 , 11, e0154751	3.7	13
118	Escalas de evaluación del riesgo tromboembólico y hemorrágico en la fibrilación auricular. <i>Revista Espanola De Cardiologia Suplementos</i> , 2016 , 16, 25-32	0.2	
117	En el camino de un mejor uso de los anticoagulantes en la fibrilación auricular no valvular. Propuesta de modificación del posicionamiento terapéutico UT/V4/23122013. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 551-553	1.5	25

116	The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion. <i>International Journal of Cardiology</i> , 2016 , 217, 42-8	3.2	4
115	New Role of Biomarkers in Atrial Fibrillation 2016 , 507-539		
114	The SAME-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective Real-world PInception Cohort Study. <i>American Journal of Medicine</i> , 2015 , 128, 1237-43	2.4	42
113	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRs). <i>Europace</i> , 2015 , 17, 1197-214	3.9	123
112	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015 , 17, 1467-507	3.9	803
111	Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015 , 68, 497-504	0.7	11
110	Biomarkers: GDF-15 and risk stratification in atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2015 , 12, 8-9	14.8	14
109	sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2015 , 45, 899-905	4.6	12
108	Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. <i>Thrombosis Journal</i> , 2015 , 13, 22	5.6	29
107	Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015 , 22, 610-7	4	15
106	New Role of Biomarkers in Atrial Fibrillation 2015 , 1-33		
105	Common Questions in Anticoagulation Management in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2014 , 6, 79-86	1.4	1
104	SAME-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. <i>American Journal of Medicine</i> , 2014 , 127, 1083-1088	2.4	94
103	Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 781-8	7	27
102	Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. <i>Stroke</i> , 2014 , 45, 696-701	6.7	32
101	Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. <i>Pharmacogenomics</i> , 2014 , 15, 987-96	2.6	8
100	Novel oral anticoagulants in cardiovascular disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 34-44	2.6	20
99	Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). <i>American Journal of Cardiology</i> , 2013 , 111, 1159-64	3	91

98	The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2199-204	15.1	144
97	Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. <i>Annals of Medicine</i> , 2013 , 45, 274-90	1.5	17
96	Creating a genotype-based dosing algorithm for acenocoumarol steady dose. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 146-53	7	29
95	The prognostic role of the adiponectin levels in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 168-73	4.6	16
94	Comparative determination and monitoring of biomarkers of necrosis and myocardial remodeling between radiofrequency ablation and cryoablation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013 , 36, 31-6	1.6	9
93	miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle. <i>Molecular Medicine</i> , 2013 , 18, 1466-72	6.2	31
92	Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. <i>Chest</i> , 2013 , 143, 179-184	5.3	143
91	Conventional and new oral anticoagulants in the treatment of chest disease and its complications. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 413-21	10.2	4
90	Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting. <i>Age and Ageing</i> , 2013 , 42, 70-5	3	11
89	Association of the thrombomodulin gene c.1418C>T polymorphism with thrombomodulin levels and with venous thrombosis risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 1435-40	9.4	24
88	Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1189-98	7	139
87	ET-1 protein and prognosis in patients with atrial fibrillation receiving anticoagulation treatment. <i>Chest</i> , 2013 , 144, 1564-1570	5.3	12
86	Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 956-60	7	88
85	Novel associations of VKORC1 variants with higher acenocoumarol requirements. <i>PLoS ONE</i> , 2013 , 8, e64469	3.7	12
84	High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1500-7	15.4	78
83	Predictive Value of the CHA2DS2-VASc Score in Atrial Fibrillation Patients at High Risk for Stroke Despite Oral Anticoagulation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 627-633	0.7	2
82	Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. <i>Revista Espanola De Cardiologia</i> , 2012 , 65, 627-33	1.5	36
81	Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2012 , 42, 1302-8	4.6	18

80	Pro: "Antidote for new anticoagulants"---specific target of inhibition requires a specific target for neutralisation. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 621-2	7	4
79	Prognostic value of mean platelet volume in patients with non-ST-elevation acute coronary syndrome. <i>Angiology</i> , 2012 , 63, 241-4	2.1	20
78	Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 459-66	6	53
77	Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012 , 5, 312-8	6.4	93
76	Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2496-504	15.1	105
75	Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: a pilot study. <i>Thrombosis Research</i> , 2011 , 128, 391-4	8.2	10
74	Is plasminogen activator inhibitor-1 (PAI-1) a surrogate marker of vascular damage?. <i>Thrombosis Research</i> , 2011 , 128, 601-2	8.2	1
73	An evaluation of the CHADS ₂ stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization. <i>Chest</i> , 2011 , 139, 1402-1409	5.3	12
72	Influence of the F12 -4 C>T polymorphism on hemostatic tests. <i>Blood Coagulation and Fibrinolysis</i> , 2010 , 21, 632-9	1	10
71	Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 650-2	7	2
70	The additive value of biomarkers to clinical risk scores in acute coronary syndrome. Are biomarkers really ready for real world usage?. <i>Heart</i> , 2010 , 96, 227-8; author reply 228	5.1	9
69	Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. <i>Annals of Medicine</i> , 2010 , 42, 562-75	1.5	10
68	Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. <i>Haematologica</i> , 2010 , 95, 863-6	6.6	14
67	Effects of atorvastatin 80 mg daily on indices of matrix remodelling in high-risk patients with ischemic heart disease. <i>International Journal of Cardiology</i> , 2010 , 139, 95-7	3.2	5
66	The prognostic value of biomarkers after a premature myocardial infarction. <i>International Journal of Cardiology</i> , 2010 , 143, 249-54	3.2	18
65	Clinical characteristics of patients with factor V Leiden or prothrombin G20210A and a first episode of venous thromboembolism. Findings from the RIETE Registry. <i>Thrombosis Research</i> , 2010 , 126, 283-6	8.2	13
64	CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. <i>Annals of Medicine</i> , 2010 , 42, 439-46	1.5	7
63	Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders. <i>Annals of Hematology</i> , 2010 , 89, 1147-54	3	3

62	Hypouricemic effect of statins: another pleiotropic benefit?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010 , 139, 1358-9	1.5	3
61	Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance. <i>Annals of Medicine</i> , 2009 , 41, 547-58	1.5	4
60	Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. <i>Thrombosis Research</i> , 2009 , 124, 174-7	8.2	58
59	Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation. <i>International Journal of Cardiology</i> , 2009 , 132, 227-32	3.2	10
58	Premature coronary artery disease in young (age . <i>International Journal of Cardiology</i> , 2009 , 136, 222-5	3.2	45
57	Pharmacogenetics in cardiovascular antithrombotic therapy. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1041-57	15.1	81
56	Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. <i>Blood</i> , 2009 , 113, 4977-9	2.2	67
55	Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. <i>European Heart Journal</i> , 2009 , 30, 139-51	9.5	61
54	Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. <i>European Heart Journal</i> , 2009 , 30, 932-9	9.5	37
53	Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 483-486	7	29
52	Implications of pharmacogenetics for oral anticoagulants metabolism. <i>Current Drug Metabolism</i> , 2009 , 10, 632-42	3.5	12
51	Premature myocardial infarction: clinical profile and angiographic findings. <i>International Journal of Cardiology</i> , 2008 , 126, 127-9	3.2	55
50	Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. <i>American Heart Journal</i> , 2008 , 156, 85-91	4.9	71
49	Gamma-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol. <i>Thrombosis Research</i> , 2008 , 122, 429-31	8.2	4
48	Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications. <i>Journal of Cardiac Failure</i> , 2008 , 14, 414-9	3.3	31
47	Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: implications for the prothrombotic state and stroke risk. <i>Annals of Medicine</i> , 2008 , 40, 553-9	1.5	13
46	Endothelial protein C receptor polymorphisms and risk of myocardial infarction. <i>Haematologica</i> , 2008 , 93, 1358-63	6.6	31
45	Letter by Roldán et al regarding article, "Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass". <i>Circulation</i> , 2008 , 117, e169; author reply e170	16.7	

44	TUBB1 Q43P polymorphism does not protect against acute coronary syndrome and premature myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 1211-1213	7	5
43	Contra: Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions? <i>Thrombosis and Haemostasis</i> , 2008 , 100, 754-755	7	13
42	Contra: Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions? Not for everybody. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 754-5	7	2
41	A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. <i>Journal of Internal Medicine</i> , 2007 , 262, 651-8	10.8	65
40	Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. <i>European Heart Journal</i> , 2007 , 28, 3006-11	9.5	29
39	Common carotid artery intima-media thickness and intracranial pulsatility index in non-ST-elevation acute coronary syndromes. <i>Cerebrovascular Diseases</i> , 2007 , 24, 338-42	3.2	10
38	The association of the beta1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. <i>Haematologica</i> , 2007 , 92, 513-8	6.6	32
37	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. <i>Blood</i> , 2007 , 109, 4258-63	2.2	90
36	Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. <i>American Journal of Cardiology</i> , 2006 , 97, 55-60	3	177
35	Effect of statins on preventing recurrence of atrial fibrillation after electrical cardioversion. <i>American Journal of Cardiology</i> , 2006 , 98, 1299-300	3	21
34	Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated. <i>Future Cardiology</i> , 2006 , 2, 197-203	1.3	
33	Is an advanced age an additive risk factor to the prothrombotic or hypercoagulable state in atrial fibrillation?. <i>International Journal of Cardiology</i> , 2006 , 110, 265-6	3.2	3
32	Antiplatelet versus anticoagulant therapies in advanced age: an unfinished task. <i>International Journal of Cardiology</i> , 2006 , 110, 271-2	3.2	3
31	A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. <i>Blood</i> , 2006 , 108, 177-83	2.2	53
30	Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy volunteers?. <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 21, 163-6	5.1	2
29	Influence of smoking habit on cardiac functional capacity and diastolic function in healthy people. <i>International Journal of Cardiology</i> , 2005 , 98, 517-8	3.2	5
28	Are there ethnic differences in the circadian variation in onset of acute myocardial infarction? A comparison of 3 ethnic groups in Birmingham, UK and Alicante, Spain. <i>International Journal of Cardiology</i> , 2005 , 100, 151-4	3.2	28
27	Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. <i>Thrombosis Research</i> , 2005 , 116, 321-5	8.2	31

26	Effect of Maximum Dose of Atorvastatin on Inflammation, Thrombogenesis, and Fibrinolysis in High-Risk Patients With Ischemic Heart Disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2005 , 58, 934-940	0.7	1
25	A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 25-9	15.1	22
24	Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. <i>American Journal of Cardiology</i> , 2005 , 95, 881-2	3	24
23	Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2005 , 94, 1294-9	7	23
22	Pharmacogenetics in cardiovascular antithrombotic therapy. <i>Current Medicinal Chemistry Cardiovascular and Hematological Agents</i> , 2005 , 3, 357-64		3
21	Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. <i>Haematologica</i> , 2005 , 90, 421-3	6.6	17
20	Genetic polymorphisms and thromboembolic risk in atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2004 , 18, 151-2	5.1	3
19	¿Podemos esperar de los polimorfismos las respuestas a nuestras dudas?. <i>Revista Espanola De Cardiologia</i> , 2004 , 57, 1129	1.5	
18	Can We Expect Polymorphisms to Answer our Questions?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2004 , 57, 1129	0.7	
17	Matrix metalloproteinases in atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 152; author reply 152-3	15.1	
16	Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. <i>Journal of Molecular and Cellular Cardiology</i> , 2004 , 37, 699-704	5.8	31
15	Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. <i>American Heart Journal</i> , 2004 , 148, 602-5	4.9	16
14	Soluble E-selectin, interleukin-6 and tissue factor in two cases of meningococcal septicaemia. <i>Blood Coagulation and Fibrinolysis</i> , 2004 , 15, 179-82	1	1
13	Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?. <i>Stroke</i> , 2003 , 34, 1181-6	6.7	80
12	Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. <i>Thrombosis and Haemostasis</i> , 2003 , 90, 1007-20	7	127
11	Role of factor XIII Val34Leu polymorphism in patients . <i>American Journal of Cardiology</i> , 2003 , 91, 1242-5	3	22
10	Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. <i>European Heart Journal</i> , 2003 , 24, 1373-80	9.5	97
9	Fibrinolytic function and atrial fibrillation. <i>Thrombosis Research</i> , 2003 , 109, 233-40	8.2	27

8	Effect of Factor XIII VAL34LEU Polymorphism on Thrombolytic Therapy in Premature Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 354-355	7	12
7	Do protein Z levels influence the prothrombotic state in atrial fibrillation?. <i>Thrombosis Research</i> , 2002 , 106, 269-70	8.2	2
6	Diurnal variation of international normalised ratio in patients under oral anticoagulation. <i>Thrombosis Research</i> , 2002 , 108, 355	8.2	
5	Prothrombin fragment F1+2 and von Willebrand factor levels and left ventricular systolic function. Peripheral versus intracardiac blood samples. <i>International Journal of Cardiology</i> , 2002 , 83, 289-90	3.2	
4	Tissue factor/tissue factor pathway inhibitor system and long-term prognosis after acute myocardial infarction. <i>International Journal of Cardiology</i> , 2001 , 78, 115-9	3.2	11
3	Anticoagulant therapy modifies fibrinolytic dysfunction in chronic atrial fibrillation. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000 , 30, 219-24		2
2	Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation. <i>American Journal of Cardiology</i> , 1999 , 84, 862-4, A9	3	21
1	Hypofibrinolysis in atrial fibrillation. <i>American Heart Journal</i> , 1998 , 136, 956-60	4.9	50